Past few months have not been that easy for Eisai, which lost quite a few patent battles and suffered financial loss lately. The company now claims that its new thyroid drug, which is ready to hit the market can bring back its glory and take the annual sales to as much as $1 billion mark in the near future. It looks forward to launching drugs for other tumor types as well after the launch of this thyroid drug.
Insights On The Matter:
The developed drug has been named Lenvatinib. It is a tyrosine kinase receptor inhibitor, which blocks the growth agents of the thyroid tumor. The results of the Phase 3 study of this drug were recently published in The New England Journal of Medicine. These results unfolded that the oral treatment of this drug elevated the chances of progression-free survival in thyroid cancer in a better way than placebo. According to reports, Eisai prepared final report and submitted it to FDA in the previous year. The regulators looked into this matter closely and reviewed the drug on priority, which made Eisai hope that it would win the approval to distribute lenvatinib within a few months time.
In an interview with The Wall Street Journal, Eisai’s representatives told that the strong potential of lenvatinib will solely depend on its capability to cure other tumors. The company is looking forward to executing further trials in liver, lung, kidney and endometrial cancers. If everything goes fine and lenvatinib clears the trial, then it can surely make more than $1 billion by 2020.
Ivan Cheung, Vice President of Eisai, claims that it will prove to be a blockbuster in the medical industry with some additional indications. Not only will it set off the previous losses of Eisai, but also provide a one stop solution for the deathly cancer disease.